Description

Lonza Group AG is a Swiss-based multinational corporation that provides a diverse range of products and services globally to the pharmaceutical, biotechnology, and nutrition industries. Its comprehensive operations are structured into four key business segments. The Biologics division specializes in contract development and manufacturing for biopharmaceutical compounds. The Small Molecules segment offers integrated services for the development and production of small molecule drug substances and their intermediate components. The Cell and Gene division is at the forefront of industrializing manufacturing processes and production for advanced cell and gene therapies. This unit also offers contract development and manufacturing services for various cell therapies (allogeneic, autologous, exosome-based) and viral vector gene therapies. Additionally, it supplies specialized raw materials and technological solutions vital for cell and gene therapy, injectable drugs, vaccines, and broader bio-manufacturing applications. Finally, the Capsules and Health Ingredients division delivers encapsulation solutions, dosage forms, and health-enhancing ingredients to both pharmaceutical and nutraceutical customers. Founded in 1897, Lonza Group AG maintains its headquarters in Basel, Switzerland.